Sufentanil - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (3)Enzymes (1)

Targets (3)Enzymes (1)Biointeractions (4)

Identification

Name

Sufentanil

Accession Number

DB00708 (APRD00671, DB05563)

Type

Small Molecule

Groups

Approved, Investigational

Description

An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. [PubChem]

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide

N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide

Sufentanil

Sufentanilo

Sufentanilum

Sufentanyl

External IDs

IDS-NS-001 / R 30730 / R 33800

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Sufentanil Citrate	S9ZFX8403R	60561-17-3	OJCZPLDERGDQRJ-UHFFFAOYSA-N	Details

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Sufenta Inj 50mcg/ml	Liquid	50 mcg	Epidural; Intravenous	Janssen Pharmaceuticals	1985-12-31	2007-11-26	Canada
Sufenta Inj 50mcg/ml	Liquid	50 mcg	Intravenous	Janssen Pharmaceutica, Division Of Janssen Ortho Inc.	1985-12-31	1996-09-10	Canada
Sufentanil Citrate	Injection	50 ug/mL	Epidural; Intravenous	Akorn	2010-12-01	Not applicable	US
Sufentanil Citrate Injection USP	Solution	50 mcg	Epidural; Intravenous	Sandoz Canada Incorporated	2001-08-01	Not applicable	Canada
Sufentanil Citrate Injection, USP	Solution	50 mcg	Epidural; Intravenous	Sterimax Inc	2016-10-18	Not applicable	Canada
Zalviso	Tablet	15 μg	Sublingual	Grunenthal Gmb H	2015-09-18	Not applicable	EU
Zalviso	Tablet	15 μg	Sublingual	Grunenthal Gmb H	2015-09-18	Not applicable	EU
Zalviso	Tablet	15 μg	Sublingual	Grunenthal Gmb H	2015-09-18	Not applicable	EU
Zalviso	Tablet	15 μg	Sublingual	Grunenthal Gmb H	2015-09-18	Not applicable	EU
Zalviso	Tablet	15 μg	Sublingual	Grunenthal Gmb H	2015-09-18	Not applicable	EU
Zalviso	Tablet	15 μg	Sublingual	Grunenthal Gmb H	2015-09-18	Not applicable	EU

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Sufentanil Citrate	Injection	.05 mg/mL	Epidural; Intravenous	West Ward Pharmaceutical	1995-12-15	Not applicable	US
Sufentanil Citrate	Injection, solution	50 ug/mL	Epidural; Intravenous	Hospira, Inc.	1996-12-11	Not applicable	US
Sufentanil Citrate	Injection	.05 mg/mL	Epidural; Intravenous	West Ward Pharmaceutical	1995-12-15	Not applicable	US
Sufentanil Citrate	Injection, solution	50 ug/mL	Epidural; Intravenous	Hospira, Inc.	1996-12-11	Not applicable	US
Sufentanil Citrate	Injection	.05 mg/mL	Epidural; Intravenous	West Ward Pharmaceutical	1995-12-15	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Chronogesic	DURECT
Disufen	Angenerico
Fastfen	Cristália
Sufenta	Janssen
Sufenta Forte	Janssen
Sufenta mite	Janssen
Sufentil	Claris Lifesciences Ltd.
Zuftil	Pisa

Brand mixtures

Not Available

Categories

UNII

AFE2YW0IIZ

CAS number

56030-54-7

Weight

Average: 386.551
Monoisotopic: 386.202798904

Chemical Formula

C₂₂H₃₀N₂O₂S

InChI Key

GGCSSNBKKAUURC-UHFFFAOYSA-N

InChI

InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3

IUPAC Name

N-[4-(methoxymethyl)-1-[2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropanamide

SMILES

CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1

Pharmacology

Indication

Used as an analgesic adjunct in anesthesia and as a primary anesthetic drug in procedures requiring assisted ventilation and in the relief of pain.

Structured Indications

Not Available

Pharmacodynamics

Sufentanil is a synthetic opioid analgesic. Sufentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Sufentanil may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Sufentanil depresses the respiratory centers, depresses the cough reflex, and constricts the pupils.

Mechanism of action

Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Sufentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids open calcium-dependent inwardly rectifying potassium channels (OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Mu-type opioid receptor	Protein	yes	agonist	Human	P35372	details
Delta-type opioid receptor	Protein	unknown	agonist	Human	P41143	details
Kappa-type opioid receptor	Protein	unknown	other	Human	P41145	details

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

265 minutes

Clearance

Not Available

Toxicity

LD₅₀: 18.7 mg/kg (IV in mice)

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2,5-Dimethoxy-4-ethylamphetamine	2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Sufentanil.	Experimental, Illicit
3,4-Methylenedioxyamphetamine	3,4-Methylenedioxyamphetamine may increase the analgesic activities of Sufentanil.	Experimental, Illicit
3,4-Methylenedioxymethamphetamine	3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Sufentanil.	Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine	4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Sufentanil.	Experimental, Illicit
7-Nitroindazole	The risk or severity of adverse effects can be increased when Sufentanil is combined with 7-Nitroindazole.	Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	Sufentanil may increase the serotonergic activities of 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.	Experimental
Acebutolol	Sufentanil may increase the bradycardic activities of Acebutolol.	Approved
Acepromazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Acepromazine.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Aceprometazine.	Approved
Acetazolamide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Acetazolamide.	Approved, Vet Approved
Aclidinium	The risk or severity of adverse effects can be increased when Aclidinium is combined with Sufentanil.	Approved
Adipiplon	The risk or severity of adverse effects can be increased when Sufentanil is combined with adipiplon.	Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Agomelatine.	Approved, Investigational
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sufentanil.	Approved
Alfaxalone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Alfaxalone.	Vet Approved
Alfentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Alfentanil.	Approved, Illicit
Alimemazine	Alimemazine may increase the hypotensive activities of Sufentanil.	Approved, Vet Approved
Aliskiren	The risk or severity of adverse effects can be increased when Aliskiren is combined with Sufentanil.	Approved, Investigational
Allopregnanolone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Sage 547.	Investigational
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Alphacetylmethadol.	Experimental, Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Alprazolam is combined with Sufentanil.	Approved, Illicit, Investigational
Alprenolol	Sufentanil may increase the bradycardic activities of Alprenolol.	Approved, Withdrawn
Alvimopan	The risk or severity of adverse effects can be increased when Sufentanil is combined with Alvimopan.	Approved
Amifostine	The risk or severity of adverse effects can be increased when Amifostine is combined with Sufentanil.	Approved, Investigational
Amiloride	The risk or severity of adverse effects can be increased when Sufentanil is combined with Amiloride.	Approved
Amiodarone	The metabolism of Sufentanil can be decreased when combined with Amiodarone.	Approved, Investigational
Amisulpride	The risk or severity of adverse effects can be increased when Sufentanil is combined with Amisulpride.	Approved, Investigational
Amitriptyline	The risk or severity of adverse effects can be increased when Sufentanil is combined with Amitriptyline.	Approved
Amlodipine	The risk or severity of adverse effects can be increased when Amlodipine is combined with Sufentanil.	Approved
Ammonium chloride	Ammonium chloride may increase the excretion rate of Sufentanil which could result in a lower serum level and potentially a reduction in efficacy.	Approved, Vet Approved
Amobarbital	The risk or severity of adverse effects can be increased when Sufentanil is combined with Amobarbital.	Approved, Illicit
Amoxapine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Amoxapine.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Amperozide.	Experimental
Amphetamine	Amphetamine may increase the analgesic activities of Sufentanil.	Approved, Illicit
Amphotericin B	The risk or severity of adverse effects can be increased when Amphotericin B is combined with Sufentanil.	Approved, Investigational
Amyl Nitrite	The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Sufentanil.	Approved
Anisotropine Methylbromide	The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Sufentanil.	Approved
Apomorphine	The risk or severity of adverse effects can be increased when Apomorphine is combined with Sufentanil.	Approved, Investigational
Apraclonidine	The risk or severity of adverse effects can be increased when Apraclonidine is combined with Sufentanil.	Approved
Aprepitant	The serum concentration of Sufentanil can be increased when it is combined with Aprepitant.	Approved, Investigational
Aripiprazole	Aripiprazole may increase the hypotensive activities of Sufentanil.	Approved, Investigational
Arotinolol	The risk or severity of adverse effects can be increased when Arotinolol is combined with Sufentanil.	Approved
Arsenic trioxide	The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sufentanil.	Approved, Investigational
Articaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Articaine.	Approved
Asenapine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Asenapine.	Approved
Atazanavir	The metabolism of Sufentanil can be decreased when combined with Atazanavir.	Approved, Investigational
Atenolol	Atenolol may increase the bradycardic activities of Sufentanil.	Approved
Atomoxetine	The metabolism of Sufentanil can be decreased when combined with Atomoxetine.	Approved
Atracurium besylate	The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Sufentanil.	Approved
Atropine	The risk or severity of adverse effects can be increased when Atropine is combined with Sufentanil.	Approved, Vet Approved
Azelastine	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Azelastine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Azelastine.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Sufentanil.	Approved
Azosemide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Azosemide.	Investigational
Baclofen	The risk or severity of adverse effects can be increased when Sufentanil is combined with Baclofen.	Approved
Barbexaclone	Barbexaclone may increase the hypotensive activities of Sufentanil.	Experimental
Barbital	The risk or severity of adverse effects can be increased when Sufentanil is combined with Barbital.	Illicit
Barnidipine	The risk or severity of adverse effects can be increased when Barnidipine is combined with Sufentanil.	Approved
Befunolol	Sufentanil may increase the bradycardic activities of Befunolol.	Experimental
Benactyzine	The risk or severity of adverse effects can be increased when Benactyzine is combined with Sufentanil.	Withdrawn
Benazepril	The risk or severity of adverse effects can be increased when Benazepril is combined with Sufentanil.	Approved, Investigational
Bendroflumethiazide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Bendroflumethiazide.	Approved
Benmoxin	Sufentanil may increase the serotonergic activities of Benmoxin.	Withdrawn
Benperidol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Benperidol.	Investigational
Benzatropine	The risk or severity of adverse effects can be increased when Benzatropine is combined with Sufentanil.	Approved
Benzocaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Benzocaine.	Approved
Benzphetamine	Benzphetamine may increase the analgesic activities of Sufentanil.	Approved, Illicit
Benzyl alcohol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Benzyl alcohol.	Approved
Bepridil	The risk or severity of adverse effects can be increased when Bepridil is combined with Sufentanil.	Approved, Withdrawn
Beractant	Sufentanil may increase the bradycardic activities of Beractant.	Approved
Betaxolol	Betaxolol may increase the bradycardic activities of Sufentanil.	Approved
Bevantolol	Sufentanil may increase the bradycardic activities of Bevantolol.	Approved
Bexarotene	The serum concentration of Sufentanil can be decreased when it is combined with Bexarotene.	Approved, Investigational
Biperiden	The risk or severity of adverse effects can be increased when Biperiden is combined with Sufentanil.	Approved
Bisoprolol	Bisoprolol may increase the bradycardic activities of Sufentanil.	Approved
BL-1020	BL-1020 may increase the hypotensive activities of Sufentanil.	Investigational
Boceprevir	The metabolism of Sufentanil can be decreased when combined with Boceprevir.	Withdrawn
Bopindolol	Sufentanil may increase the bradycardic activities of Bopindolol.	Approved
Bortezomib	The metabolism of Sufentanil can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Sufentanil can be decreased when it is combined with Bosentan.	Approved, Investigational
Bretylium	Bretylium may increase the bradycardic activities of Sufentanil.	Approved
Brexpiprazole	The risk or severity of adverse effects can be increased when Sufentanil is combined with Brexpiprazole.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Brimonidine.	Approved
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved
Bromazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Bromazepam.	Approved, Illicit
Bromocriptine	The risk or severity of adverse effects can be increased when Bromocriptine is combined with Sufentanil.	Approved, Investigational
Brompheniramine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Brompheniramine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Brotizolam.	Approved, Withdrawn
Bucindolol	Sufentanil may increase the bradycardic activities of Bucindolol.	Investigational
Bufuralol	Sufentanil may increase the bradycardic activities of Bufuralol.	Experimental, Investigational
Bumetanide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Bumetanide.	Approved
Bupivacaine	The risk or severity of adverse effects can be increased when Bupivacaine is combined with Sufentanil.	Approved, Investigational
Bupranolol	Sufentanil may increase the bradycardic activities of Bupranolol.	Approved
Buprenorphine	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The risk or severity of adverse effects can be increased when Buspirone is combined with Sufentanil.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Sufentanil.	Approved, Illicit
Butalbital	The risk or severity of adverse effects can be increased when Sufentanil is combined with Butalbital.	Approved, Illicit
Butethal	The risk or severity of adverse effects can be increased when Sufentanil is combined with Butethal.	Approved, Illicit
Butorphanol	Butorphanol may decrease the analgesic activities of Sufentanil.	Approved, Illicit, Vet Approved
Calfactant	Sufentanil may increase the bradycardic activities of Calfactant.	Approved
Canagliflozin	The risk or severity of adverse effects can be increased when Canagliflozin is combined with Sufentanil.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Candesartan is combined with Sufentanil.	Approved
Canrenoic acid	The risk or severity of adverse effects can be increased when Sufentanil is combined with Canrenoic acid.	Approved, Withdrawn
Canrenone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Canrenone.	Investigational
Captopril	The risk or severity of adverse effects can be increased when Captopril is combined with Sufentanil.	Approved
Carbamazepine	The metabolism of Sufentanil can be increased when combined with Carbamazepine.	Approved, Investigational
Carbetocin	The risk or severity of adverse effects can be increased when Carbetocin is combined with Sufentanil.	Approved
Carbinoxamine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Carbinoxamine.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Carfentanil.	Illicit, Vet Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Carisoprodol.	Approved
Caroxazone	Sufentanil may increase the serotonergic activities of Caroxazone.	Withdrawn
Carteolol	Carteolol may increase the bradycardic activities of Sufentanil.	Approved
Carvedilol	Sufentanil may increase the bradycardic activities of Carvedilol.	Approved, Investigational
Celiprolol	Sufentanil may increase the bradycardic activities of Celiprolol.	Approved, Investigational
Ceritinib	Sufentanil may increase the bradycardic activities of Ceritinib.	Approved
Cetirizine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cetirizine.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chloral hydrate.	Approved, Illicit, Vet Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sufentanil.	Approved, Illicit
Chlormezanone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlormezanone.	Approved, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chloroprocaine.	Approved
Chlorothiazide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorothiazide.	Approved, Vet Approved
Chlorphenamine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorphenamine.	Approved
Chlorphenoxamine	The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Sufentanil.	Withdrawn
Chlorphentermine	Chlorphentermine may increase the analgesic activities of Sufentanil.	Illicit, Withdrawn
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sufentanil.	Approved, Vet Approved
Chlorprothixene	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorprothixene.	Approved, Withdrawn
Chlorthalidone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorthalidone.	Approved
Chlorzoxazone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorzoxazone.	Approved
Cicletanine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cicletanine.	Investigational
Cilazapril	The risk or severity of adverse effects can be increased when Cilazapril is combined with Sufentanil.	Approved
Cilnidipine	The risk or severity of adverse effects can be increased when Cilnidipine is combined with Sufentanil.	Approved
Cinchocaine	The risk or severity of adverse effects can be increased when Cinchocaine is combined with Sufentanil.	Approved, Vet Approved
Citalopram	Sufentanil may increase the serotonergic activities of Citalopram.	Approved
Clarithromycin	The metabolism of Sufentanil can be decreased when combined with Clarithromycin.	Approved
Clemastine	The metabolism of Sufentanil can be decreased when combined with Clemastine.	Approved
Clevidipine	The risk or severity of adverse effects can be increased when Clevidipine is combined with Sufentanil.	Approved
Clidinium	The risk or severity of adverse effects can be increased when Sufentanil is combined with Clidinium.	Approved
Clobazam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Clobazam.	Approved, Illicit
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Sufentanil.	Approved, Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Clomipramine.	Approved, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Clonazepam.	Approved, Illicit
Clonidine	Clonidine may increase the bradycardic activities of Sufentanil.	Approved
Clorazepate	The risk or severity of adverse effects can be increased when Clorazepate is combined with Sufentanil.	Approved, Illicit
Clotrimazole	The metabolism of Sufentanil can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The risk or severity of adverse effects can be increased when Clozapine is combined with Sufentanil.	Approved
Cobicistat	The metabolism of Sufentanil can be decreased when combined with Cobicistat.	Approved
Cocaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cocaine.	Approved, Illicit
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Sufentanil.	Approved, Illicit
Conivaptan	The serum concentration of Sufentanil can be increased when it is combined with Conivaptan.	Approved, Investigational
Crizotinib	The metabolism of Sufentanil can be decreased when combined with Crizotinib.	Approved
Cyclizine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclizine.	Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclobenzaprine.	Approved
Cyclopentolate	The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Sufentanil.	Approved
Cyclosporine	The metabolism of Sufentanil can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyclothiazide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclothiazide.	Approved
Cyproheptadine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Cyproheptadine.	Approved
Dabrafenib	The serum concentration of Sufentanil can be decreased when it is combined with Dabrafenib.	Approved
Dantrolene	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dantrolene.	Approved
Dapagliflozin	The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Sufentanil.	Approved
Dapiprazole	The risk or severity of adverse effects can be increased when Dapiprazole is combined with Sufentanil.	Approved
Dapoxetine	Sufentanil may increase the serotonergic activities of Dapoxetine.	Investigational
Darifenacin	The risk or severity of adverse effects can be increased when Darifenacin is combined with Sufentanil.	Approved, Investigational
Darunavir	The metabolism of Sufentanil can be decreased when combined with Darunavir.	Approved
Dasatinib	The serum concentration of Sufentanil can be increased when it is combined with Dasatinib.	Approved, Investigational
Deferasirox	The serum concentration of Sufentanil can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The metabolism of Sufentanil can be decreased when combined with Delavirdine.	Approved
Deramciclane	The risk or severity of adverse effects can be increased when Sufentanil is combined with deramciclane.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Sufentanil is combined with Desflurane.	Approved
Desipramine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Desipramine.	Approved
Desloratadine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Desloratadine.	Approved, Investigational
Desmopressin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Desmopressin.	Approved
Desvenlafaxine	Sufentanil may increase the serotonergic activities of Desvenlafaxine.	Approved
Dexamethasone	The serum concentration of Sufentanil can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dexbrompheniramine.	Approved
Dexetimide	The risk or severity of adverse effects can be increased when Dexetimide is combined with Sufentanil.	Withdrawn
Dexmedetomidine	Dexmedetomidine may increase the bradycardic activities of Sufentanil.	Approved, Vet Approved
Dextroamphetamine	Dextroamphetamine may increase the analgesic activities of Sufentanil.	Approved, Illicit
Dextromoramide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dextromoramide.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sufentanil.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dezocine.	Approved
Diazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Diazepam.	Approved, Illicit, Vet Approved
Diclofenamide	The risk or severity of adverse effects can be increased when Diclofenamide is combined with Sufentanil.	Approved
Dicyclomine	The risk or severity of adverse effects can be increased when Dicyclomine is combined with Sufentanil.	Approved
Diethylpropion	Diethylpropion may increase the analgesic activities of Sufentanil.	Approved, Illicit
Difenoxin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Difenoxin.	Approved, Illicit
Digoxin	Digoxin may increase the bradycardic activities of Sufentanil.	Approved
Dihydrocodeine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydrocodeine.	Approved, Illicit
Dihydroergotamine	The metabolism of Sufentanil can be decreased when combined with Dihydroergotamine.	Approved
Dihydroetorphine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydroetorphine.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydromorphine.	Experimental, Illicit
Diltiazem	The metabolism of Sufentanil can be decreased when combined with Diltiazem.	Approved
Dimenhydrinate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Dimenhydrinate.	Approved
Dinutuximab	The risk or severity of adverse effects can be increased when Dinutuximab is combined with Sufentanil.	Approved
Diphenhydramine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Diphenhydramine.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Diphenoxylate.	Approved, Illicit
Dipyridamole	The risk or severity of adverse effects can be increased when Dipyridamole is combined with Sufentanil.	Approved
Donepezil	Sufentanil may increase the bradycardic activities of Donepezil.	Approved
Doxazosin	The risk or severity of adverse effects can be increased when Doxazosin is combined with Sufentanil.	Approved
Doxepin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Doxepin.	Approved
Doxycycline	The metabolism of Sufentanil can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved, Vet Approved
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved, Illicit
Dronedarone	The metabolism of Sufentanil can be decreased when combined with Dronedarone.	Approved
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved, Vet Approved
Drospirenone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Drospirenone.	Approved
Drotebanol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Drotebanol.	Experimental, Illicit
Duloxetine	Sufentanil may increase the orthostatic hypotensive activities of Duloxetine.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Dyclonine is combined with Sufentanil.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ecgonine.	Experimental, Illicit
Ecopipam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ecopipam.	Investigational
Efavirenz	The serum concentration of Sufentanil can be decreased when it is combined with Efavirenz.	Approved, Investigational
Efonidipine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Efonidipine.	Approved
Eltanolone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Pregnanolone.	Investigational
Eluxadoline	Sufentanil may increase the constipating activities of Eluxadoline.	Approved
Empagliflozin	The risk or severity of adverse effects can be increased when Empagliflozin is combined with Sufentanil.	Approved
Enalapril	The risk or severity of adverse effects can be increased when Enalapril is combined with Sufentanil.	Approved, Vet Approved
Enalaprilat	The risk or severity of adverse effects can be increased when Enalaprilat is combined with Sufentanil.	Approved
Enflurane	The risk or severity of adverse effects can be increased when Enflurane is combined with Sufentanil.	Approved, Vet Approved
Entacapone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Entacapone.	Approved, Investigational
Enzalutamide	The serum concentration of Sufentanil can be decreased when it is combined with Enzalutamide.	Approved
Eplerenone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Eplerenone.	Approved
Epoprostenol	The risk or severity of adverse effects can be increased when Epoprostenol is combined with Sufentanil.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Eprosartan is combined with Sufentanil.	Approved
Erythromycin	The metabolism of Sufentanil can be decreased when combined with Erythromycin.	Approved, Vet Approved
Escitalopram	Sufentanil may increase the serotonergic activities of Escitalopram.	Approved, Investigational
Eslicarbazepine acetate	The serum concentration of Sufentanil can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Esmolol	Esmolol may increase the bradycardic activities of Sufentanil.	Approved
Estazolam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Estazolam.	Approved, Illicit
Eszopiclone	The risk or severity of adverse effects can be increased when Eszopiclone is combined with Sufentanil.	Approved
Etacrynic acid	The risk or severity of adverse effects can be increased when Sufentanil is combined with Etacrynic acid.	Approved
Ethanol	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sufentanil.	Approved, Illicit, Withdrawn
Ethopropazine	The risk or severity of adverse effects can be increased when Ethopropazine is combined with Sufentanil.	Approved
Ethosuximide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethosuximide.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethotoin.	Approved
Ethoxzolamide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethoxzolamide.	Withdrawn
Ethyl carbamate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl carbamate.	Withdrawn
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl loflazepate.	Approved, Illicit
Ethylmorphine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ethylmorphine.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Etidocaine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Etifoxine.	Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Etizolam.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Etomidate is combined with Sufentanil.	Approved
Etoperidone	Sufentanil may increase the serotonergic activities of Etoperidone.	Approved
Etorphine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Etorphine.	Illicit, Vet Approved
Etravirine	The serum concentration of Sufentanil can be decreased when it is combined with Etravirine.	Approved
Ezogabine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ezogabine.	Approved
Felbamate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Felbamate.	Approved
Felodipine	The risk or severity of adverse effects can be increased when Felodipine is combined with Sufentanil.	Approved, Investigational
Fencamfamine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Fencamfamine.	Approved, Illicit, Withdrawn
Fenoldopam	The risk or severity of adverse effects can be increased when Fenoldopam is combined with Sufentanil.	Approved
Fentanyl	The risk or severity of adverse effects can be increased when Sufentanil is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The risk or severity of adverse effects can be increased when Fesoterodine is combined with Sufentanil.	Approved
Fexofenadine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Fexofenadine.	Approved
Fimasartan	The risk or severity of adverse effects can be increased when Fimasartan is combined with Sufentanil.	Approved
Fingolimod	Sufentanil may increase the bradycardic activities of Fingolimod.	Approved, Investigational
Flibanserin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Flibanserin.	Approved
Fluconazole	The metabolism of Sufentanil can be decreased when combined with Fluconazole.	Approved
Fludiazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Fludiazepam.	Approved, Illicit
Flunarizine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Flunarizine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Flunitrazepam.	Approved, Illicit
Fluoxetine	Sufentanil may increase the serotonergic activities of Fluoxetine.	Approved, Vet Approved
Flupentixol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Flupentixol.	Approved, Withdrawn
Fluphenazine	The risk or severity of adverse effects can be increased when Fluphenazine is combined with Sufentanil.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Flurazepam is combined with Sufentanil.	Approved, Illicit
Fluspirilene	The risk or severity of adverse effects can be increased when Sufentanil is combined with Fluspirilene.	Approved
Fluticasone propionate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Fluticasone Propionate.	Approved
Fluvoxamine	The metabolism of Sufentanil can be decreased when combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The metabolism of Sufentanil can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Sufentanil can be increased when it is combined with Fosaprepitant.	Approved
Fosinopril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Sufentanil.	Approved
Fosphenytoin	The metabolism of Sufentanil can be increased when combined with Fosphenytoin.	Approved
Fospropofol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Fospropofol.	Approved, Illicit
Furazolidone	Sufentanil may increase the serotonergic activities of Furazolidone.	Approved, Vet Approved
Furosemide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Furosemide.	Approved, Vet Approved
Fusidic Acid	The serum concentration of Sufentanil can be increased when it is combined with Fusidic Acid.	Approved
Gabapentin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Gabapentin.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Sufentanil is combined with gabapentin enacarbil.	Approved
Galantamine	Galantamine may increase the bradycardic activities of Sufentanil.	Approved
Gallamine Triethiodide	The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Sufentanil.	Approved
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Sufentanil is combined with Gamma Hydroxybutyric Acid.	Approved, Illicit
Gepirone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Gepirone.	Investigational
Glutethimide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Glutethimide.	Approved, Illicit
Glycopyrronium	The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Sufentanil.	Approved, Investigational, Vet Approved
Guanfacine	Sufentanil may increase the bradycardic activities of Guanfacine.	Approved, Investigational
Halazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Halazepam.	Approved, Illicit, Withdrawn
Haloperidol	The risk or severity of adverse effects can be increased when Haloperidol is combined with Sufentanil.	Approved
Halothane	The risk or severity of adverse effects can be increased when Sufentanil is combined with Halothane.	Approved, Vet Approved
Heroin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Heroin.	Approved, Illicit
Hexamethonium	The risk or severity of adverse effects can be increased when Hexamethonium is combined with Sufentanil.	Experimental
Hexobarbital	The risk or severity of adverse effects can be increased when Sufentanil is combined with Hexobarbital.	Approved
Hydracarbazine	Sufentanil may increase the serotonergic activities of Hydracarbazine.	Experimental
Hydralazine	The risk or severity of adverse effects can be increased when Hydralazine is combined with Sufentanil.	Approved
Hydrochlorothiazide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Hydrochlorothiazide.	Approved, Vet Approved
Hydrocodone	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydroflumethiazide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Hydroflumethiazide.	Approved
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Sufentanil.	Approved, Illicit
Hydroxyamphetamine	Hydroxyamphetamine hydrobromide may increase the analgesic activities of Sufentanil.	Approved
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved
Hyoscyamine	The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Sufentanil.	Approved
Idelalisib	The serum concentration of Sufentanil can be increased when it is combined with Idelalisib.	Approved
Iloperidone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Iloperidone.	Approved
Iloprost	The risk or severity of adverse effects can be increased when Iloprost is combined with Sufentanil.	Approved, Investigational
Imatinib	The metabolism of Sufentanil can be decreased when combined with Imatinib.	Approved
Imidapril	The risk or severity of adverse effects can be increased when Imidapril is combined with Sufentanil.	Investigational
Imipramine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Imipramine.	Approved
Indalpine	Sufentanil may increase the serotonergic activities of Indalpine.	Investigational, Withdrawn
Indapamide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Indapamide.	Approved
Indenolol	Sufentanil may increase the bradycardic activities of Indenolol.	Withdrawn
Indinavir	The metabolism of Sufentanil can be decreased when combined with Indinavir.	Approved
Indoramin	The risk or severity of adverse effects can be increased when Indoramin is combined with Sufentanil.	Withdrawn
Ipratropium bromide	The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Sufentanil.	Approved
Iproclozide	Sufentanil may increase the serotonergic activities of Iproclozide.	Withdrawn
Iproniazid	Sufentanil may increase the serotonergic activities of Iproniazid.	Withdrawn
Irbesartan	The risk or severity of adverse effects can be increased when Irbesartan is combined with Sufentanil.	Approved, Investigational
Isavuconazonium	The metabolism of Sufentanil can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isocarboxazid	Sufentanil may increase the serotonergic activities of Isocarboxazid.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Sufentanil is combined with Isoflurane.	Approved, Vet Approved
Isosorbide Dinitrate	The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Sufentanil.	Approved
Isosorbide Mononitrate	The risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Sufentanil.	Approved
Isoxsuprine	The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Sufentanil.	Approved, Withdrawn
Isradipine	The metabolism of Sufentanil can be decreased when combined with Isradipine.	Approved
Itraconazole	The metabolism of Sufentanil can be decreased when combined with Itraconazole.	Approved, Investigational
Ivabradine	Sufentanil may increase the bradycardic activities of Ivabradine.	Approved
Ivacaftor	The serum concentration of Sufentanil can be increased when it is combined with Ivacaftor.	Approved
Ketamine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ketamine.	Approved, Vet Approved
Ketazolam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ketazolam.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ketobemidone.	Approved
Ketoconazole	The metabolism of Sufentanil can be decreased when combined with Ketoconazole.	Approved, Investigational
Labetalol	Labetalol may increase the bradycardic activities of Sufentanil.	Approved
Lacidipine	The risk or severity of adverse effects can be increased when Lacidipine is combined with Sufentanil.	Approved
Lacosamide	Sufentanil may increase the atrioventricular blocking (AV block) activities of Lacosamide.	Approved
Lamotrigine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Lamotrigine.	Approved, Investigational
Landiolol	Sufentanil may increase the bradycardic activities of Aop200704.	Investigational
Lanreotide	Sufentanil may increase the bradycardic activities of Lanreotide.	Approved
Lercanidipine	The risk or severity of adverse effects can be increased when Lercanidipine is combined with Sufentanil.	Approved, Investigational
Levetiracetam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Levetiracetam.	Approved, Investigational
Levobunolol	Sufentanil may increase the bradycardic activities of Levobunolol.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Levobupivacaine.	Approved
Levocabastine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Levocabastine.	Approved
Levocetirizine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Levocetirizine.	Approved
Levodopa	Sufentanil may increase the orthostatic hypotensive activities of Levodopa.	Approved
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Levomethadyl Acetate.	Approved
Levomilnacipran	Sufentanil may increase the serotonergic activities of Levomilnacipran.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Levorphanol.	Approved
Levosimendan	The risk or severity of adverse effects can be increased when Levosimendan is combined with Sufentanil.	Approved, Investigational
Lidocaine	The risk or severity of adverse effects can be increased when Lidocaine is combined with Sufentanil.	Approved, Vet Approved
Lisdexamfetamine	Lisdexamfetamine may increase the analgesic activities of Sufentanil.	Approved, Investigational
Lisinopril	The risk or severity of adverse effects can be increased when Lisinopril is combined with Sufentanil.	Approved, Investigational
Lithium	The risk or severity of adverse effects can be increased when Sufentanil is combined with Lithium.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Lofentanil.	Illicit
Lofexidine	The risk or severity of adverse effects can be increased when Lofexidine is combined with Sufentanil.	Approved, Investigational
Lopinavir	The metabolism of Sufentanil can be decreased when combined with Lopinavir.	Approved
Loratadine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Loratadine.	Approved
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Sufentanil.	Approved
Losartan	The risk or severity of adverse effects can be increased when Losartan is combined with Sufentanil.	Approved
Lovastatin	The metabolism of Sufentanil can be decreased when combined with Lovastatin.	Approved, Investigational
Loxapine	The risk or severity of adverse effects can be increased when Loxapine is combined with Sufentanil.	Approved
Lucinactant	Sufentanil may increase the bradycardic activities of Lucinactant.	Approved
Luliconazole	The serum concentration of Sufentanil can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The metabolism of Sufentanil can be increased when combined with Lumacaftor.	Approved
Lurasidone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Lurasidone.	Approved
Magnesium Sulfate	Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved, Vet Approved
Mannitol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Mannitol.	Approved, Investigational
Maprotiline	The risk or severity of adverse effects can be increased when Sufentanil is combined with Maprotiline.	Approved
Mebanazine	Sufentanil may increase the serotonergic activities of Mebanazine.	Withdrawn
Mecamylamine	The risk or severity of adverse effects can be increased when Mecamylamine is combined with Sufentanil.	Approved
Meclizine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Meclizine.	Approved
Melatonin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Melatonin.	Approved, Nutraceutical, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Melperone.	Approved
Mephedrone	Mephedrone may increase the analgesic activities of Sufentanil.	Investigational
Mephentermine	Mephentermine may increase the analgesic activities of Sufentanil.	Approved
Mepivacaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Mepivacaine.	Approved, Vet Approved
Meprobamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Sufentanil.	Approved, Illicit
Mersalyl	The risk or severity of adverse effects can be increased when Sufentanil is combined with Mersalyl.	Approved
Mesoridazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Mesoridazine.	Approved
Metaxalone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Metaxalone.	Approved
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Sufentanil.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methadyl Acetate.	Approved, Illicit
Methamphetamine	Methamphetamine may increase the analgesic activities of Sufentanil.	Approved, Illicit
Methantheline	The risk or severity of adverse effects can be increased when Methantheline is combined with Sufentanil.	Approved
Methapyrilene	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methapyrilene.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methaqualone.	Illicit, Withdrawn
Methazolamide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methazolamide.	Approved
Methocarbamol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methocarbamol.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Methohexital is combined with Sufentanil.	Approved
Methotrimeprazine	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved
Methoxyflurane	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methoxyflurane.	Approved, Vet Approved
Methsuximide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methsuximide.	Approved
Methyclothiazide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methyclothiazide.	Approved
Methyldopa	Sufentanil may increase the bradycardic activities of Methyldopa.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when Sufentanil is combined with ECGONINE METHYL ESTER.	Experimental
Methylene blue	Sufentanil may increase the serotonergic activities of Methylene blue.	Investigational
Methylphenobarbital	The risk or severity of adverse effects can be increased when Sufentanil is combined with Methylphenobarbital.	Approved
Metipranolol	Sufentanil may increase the bradycardic activities of Metipranolol.	Approved
Metixene	The risk or severity of adverse effects can be increased when Metixene is combined with Sufentanil.	Approved
Metolazone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Metolazone.	Approved
Metoprolol	Metoprolol may increase the bradycardic activities of Sufentanil.	Approved, Investigational
Metyrosine	Sufentanil may increase the sedative activities of Metyrosine.	Approved
Midazolam	The risk or severity of adverse effects can be increased when Midazolam is combined with Sufentanil.	Approved, Illicit
Mifepristone	The serum concentration of Sufentanil can be increased when it is combined with Mifepristone.	Approved, Investigational
Milnacipran	Sufentanil may increase the serotonergic activities of Milnacipran.	Approved
Minaprine	Sufentanil may increase the serotonergic activities of Minaprine.	Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved, Investigational
Minoxidil	The risk or severity of adverse effects can be increased when Minoxidil is combined with Sufentanil.	Approved
Mirtazapine	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
Mitotane	The serum concentration of Sufentanil can be decreased when it is combined with Mitotane.	Approved
MMDA	MMDA may increase the analgesic activities of Sufentanil.	Experimental, Illicit
Moclobemide	Sufentanil may increase the serotonergic activities of Moclobemide.	Approved
Modafinil	The serum concentration of Sufentanil can be decreased when it is combined with Modafinil.	Approved, Investigational
Moexipril	The risk or severity of adverse effects can be increased when Moexipril is combined with Sufentanil.	Approved
Molindone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Molindone.	Approved
Moricizine	Moricizine may increase the hypotensive activities of Sufentanil.	Approved, Withdrawn
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Sufentanil.	Approved, Investigational
Moxonidine	The risk or severity of adverse effects can be increased when Moxonidine is combined with Sufentanil.	Approved
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved, Investigational
Nadolol	Sufentanil may increase the bradycardic activities of Nadolol.	Approved
Nafcillin	The serum concentration of Sufentanil can be decreased when it is combined with Nafcillin.	Approved
Nalbuphine	Nalbuphine may decrease the analgesic activities of Sufentanil.	Approved
Naltrexone	The therapeutic efficacy of Sufentanil can be decreased when used in combination with Naltrexone.	Approved, Investigational, Vet Approved
Nebivolol	Sufentanil may increase the bradycardic activities of Nebivolol.	Approved, Investigational
Nefazodone	The metabolism of Sufentanil can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The metabolism of Sufentanil can be decreased when combined with Nelfinavir.	Approved
Nesiritide	The risk or severity of adverse effects can be increased when Nesiritide is combined with Sufentanil.	Approved, Investigational
Netupitant	The serum concentration of Sufentanil can be increased when it is combined with Netupitant.	Approved
Nevirapine	The metabolism of Sufentanil can be increased when combined with Nevirapine.	Approved
Nialamide	Sufentanil may increase the serotonergic activities of Nialamide.	Withdrawn
Nicardipine	The risk or severity of adverse effects can be increased when Nicardipine is combined with Sufentanil.	Approved
Nicorandil	Nicorandil may increase the hypotensive activities of Sufentanil.	Approved
Nifedipine	The risk or severity of adverse effects can be increased when Nifedipine is combined with Sufentanil.	Approved
Nilotinib	The metabolism of Sufentanil can be decreased when combined with Nilotinib.	Approved, Investigational
Nilvadipine	The risk or severity of adverse effects can be increased when Nilvadipine is combined with Sufentanil.	Approved
Nimodipine	The risk or severity of adverse effects can be increased when Nimodipine is combined with Sufentanil.	Approved
Nisoldipine	The risk or severity of adverse effects can be increased when Nisoldipine is combined with Sufentanil.	Approved
Nitrazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Nitrazepam.	Approved
Nitrendipine	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Sufentanil.	Approved
Nitric Oxide	The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sufentanil.	Approved
Nitroglycerin	The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Sufentanil.	Approved, Investigational
Nitroprusside	The risk or severity of adverse effects can be increased when Nitroprusside is combined with Sufentanil.	Approved
Nitrous oxide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Nitrous oxide.	Approved, Vet Approved
Norflurane	The risk or severity of adverse effects can be increased when Sufentanil is combined with 1,1,1,2 Tetrafluoroethane.	Investigational
Normethadone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Normethadone.	Approved, Illicit
Nortriptyline	The risk or severity of adverse effects can be increased when Sufentanil is combined with Nortriptyline.	Approved
Obinutuzumab	The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Sufentanil.	Approved
Octamoxin	Sufentanil may increase the serotonergic activities of Octamoxin.	Withdrawn
Octreotide	Octreotide may increase the bradycardic activities of Sufentanil.	Approved, Investigational
Olanzapine	The risk or severity of adverse effects can be increased when Olanzapine is combined with Sufentanil.	Approved, Investigational
Olaparib	The metabolism of Sufentanil can be decreased when combined with Olaparib.	Approved
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Sufentanil.	Approved, Investigational
Olopatadine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Olopatadine.	Approved
Ondansetron	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ondansetron.	Approved
Opium	The risk or severity of adverse effects can be increased when Sufentanil is combined with Opium.	Approved, Illicit
Orphenadrine	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Sufentanil is combined with Osanetant.	Investigational
Osimertinib	The serum concentration of Sufentanil can be increased when it is combined with Osimertinib.	Approved
Oxazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxazepam.	Approved
Oxethazaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxetacaine.	Investigational
Oxprenolol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxprenolol.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxybuprocaine.	Approved
Oxybutynin	The risk or severity of adverse effects can be increased when Oxybutynin is combined with Sufentanil.	Approved, Investigational
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Sufentanil.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Oxymorphone.	Approved, Investigational, Vet Approved
Oxyphenonium	The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Sufentanil.	Approved
Paclitaxel	The risk or severity of adverse effects can be increased when Paclitaxel is combined with Sufentanil.	Approved, Vet Approved
Palbociclib	The serum concentration of Sufentanil can be increased when it is combined with Palbociclib.	Approved
Paliperidone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Paliperidone.	Approved
Pancuronium	The risk or severity of adverse effects can be increased when Pancuronium is combined with Sufentanil.	Approved
Papaverine	The risk or severity of adverse effects can be increased when Papaverine is combined with Sufentanil.	Approved
Paraldehyde	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved
Pargyline	Sufentanil may increase the serotonergic activities of Pargyline.	Approved
Paroxetine	Sufentanil may increase the serotonergic activities of Paroxetine.	Approved, Investigational
Pasireotide	Sufentanil may increase the bradycardic activities of Pasireotide.	Approved
Pegvisomant	The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Sufentanil.	Approved
Penbutolol	Sufentanil may increase the bradycardic activities of Penbutolol.	Approved, Investigational
Pentazocine	Pentazocine may decrease the analgesic activities of Sufentanil.	Approved, Vet Approved
Pentobarbital	The metabolism of Sufentanil can be increased when combined with Pentobarbital.	Approved, Vet Approved
Pentolinium	The risk or severity of adverse effects can be increased when Pentolinium is combined with Sufentanil.	Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved
Perazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Perazine.	Investigational
Perindopril	The risk or severity of adverse effects can be increased when Perindopril is combined with Sufentanil.	Approved
Perospirone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Perospirone.	Approved
Perphenazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Perphenazine.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Sufentanil.	Approved
Phenelzine	Sufentanil may increase the serotonergic activities of Phenelzine.	Approved
Pheniprazine	Sufentanil may increase the serotonergic activities of Pheniprazine.	Withdrawn
Phenobarbital	The metabolism of Sufentanil can be increased when combined with Phenobarbital.	Approved
Phenoxybenzamine	The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Sufentanil.	Approved
Phenoxypropazine	Sufentanil may increase the serotonergic activities of Phenoxypropazine.	Withdrawn
Phentermine	Phentermine may increase the analgesic activities of Sufentanil.	Approved, Illicit
Phentolamine	The risk or severity of adverse effects can be increased when Phentolamine is combined with Sufentanil.	Approved
Phenytoin	The metabolism of Sufentanil can be increased when combined with Phenytoin.	Approved, Vet Approved
Pimozide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Pimozide.	Approved
Pindolol	Sufentanil may increase the bradycardic activities of Pindolol.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Pipamperone.	Approved
Pipecuronium	The risk or severity of adverse effects can be increased when Pipecuronium is combined with Sufentanil.	Approved
Pipotiazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Pipotiazine.	Approved
Pirenzepine	The risk or severity of adverse effects can be increased when Pirenzepine is combined with Sufentanil.	Approved
Piretanide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Piretanide.	Experimental
Piritramide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Piritramide.	Investigational
Pirlindole	Sufentanil may increase the serotonergic activities of Pirlindole.	Approved
Pivhydrazine	Sufentanil may increase the serotonergic activities of Pivhydrazine.	Withdrawn
Polythiazide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Polythiazide.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Pomalidomide.	Approved
Poractant alfa	Sufentanil may increase the bradycardic activities of Poractant alfa.	Approved
Posaconazole	The metabolism of Sufentanil can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Potassium	The risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium.	Approved
Potassium Citrate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium Citrate.	Approved, Vet Approved
Practolol	Sufentanil may increase the bradycardic activities of Practolol.	Approved
Pramipexole	Sufentanil may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Pramocaine.	Approved
Prazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Prazepam.	Approved, Illicit
Prazosin	The risk or severity of adverse effects can be increased when Prazosin is combined with Sufentanil.	Approved
Pregabalin	The risk or severity of adverse effects can be increased when Pregabalin is combined with Sufentanil.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Prilocaine.	Approved
Primidone	The metabolism of Sufentanil can be increased when combined with Primidone.	Approved, Vet Approved
Procaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Procaine.	Approved, Investigational, Vet Approved
Prochlorperazine	The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sufentanil.	Approved, Vet Approved
Procyclidine	The risk or severity of adverse effects can be increased when Procyclidine is combined with Sufentanil.	Approved
Promazine	The risk or severity of adverse effects can be increased when Promazine is combined with Sufentanil.	Approved, Vet Approved
Promethazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Promethazine.	Approved
Propafenone	Sufentanil may increase the bradycardic activities of Propafenone.	Approved
Propantheline	The risk or severity of adverse effects can be increased when Propantheline is combined with Sufentanil.	Approved
Proparacaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Proparacaine.	Approved, Vet Approved
Propiverine	The risk or severity of adverse effects can be increased when Propiverine is combined with Sufentanil.	Investigational
Propofol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Propofol.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Propoxycaine.	Approved
Propranolol	Propranolol may increase the bradycardic activities of Sufentanil.	Approved, Investigational
Protriptyline	The risk or severity of adverse effects can be increased when Sufentanil is combined with Protriptyline.	Approved
Pseudoephedrine	Pseudoephedrine may increase the analgesic activities of Sufentanil.	Approved
Quazepam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Quazepam.	Approved, Illicit
Quetiapine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Quetiapine.	Approved
Quinapril	The risk or severity of adverse effects can be increased when Quinapril is combined with Sufentanil.	Approved, Investigational
Quinethazone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Quinethazone.	Approved
Quinidine	The risk or severity of adverse effects can be increased when Quinidine is combined with Sufentanil.	Approved
Raclopride	The risk or severity of adverse effects can be increased when Sufentanil is combined with Raclopride.	Investigational
Ramelteon	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ramelteon.	Approved, Investigational
Ramipril	The risk or severity of adverse effects can be increased when Ramipril is combined with Sufentanil.	Approved
Ramosetron	Sufentanil may increase the constipating activities of Ramosetron.	Approved
Ranolazine	The metabolism of Sufentanil can be decreased when combined with Ranolazine.	Approved, Investigational
Rasagiline	Sufentanil may increase the serotonergic activities of Rasagiline.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Remifentanil.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Remoxipride is combined with Sufentanil.	Approved, Withdrawn
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Sufentanil.	Approved
Rifabutin	The metabolism of Sufentanil can be increased when combined with Rifabutin.	Approved
Rifampicin	The metabolism of Sufentanil can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Sufentanil can be increased when combined with Rifapentine.	Approved
Riociguat	The risk or severity of adverse effects can be increased when Riociguat is combined with Sufentanil.	Approved
Risperidone	Sufentanil may increase the hypotensive activities of Risperidone.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ritanserin.	Investigational
Ritobegron	Ritobegron may increase the analgesic activities of Sufentanil.	Investigational
Ritonavir	The metabolism of Sufentanil can be decreased when combined with Ritonavir.	Approved, Investigational
Rivastigmine	Sufentanil may increase the bradycardic activities of Rivastigmine.	Approved, Investigational
Rolofylline	The risk or severity of adverse effects can be increased when Sufentanil is combined with Rolofylline.	Investigational
Ropinirole	Sufentanil may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sufentanil.	Approved
Rotigotine	Sufentanil may increase the sedative activities of Rotigotine.	Approved
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Sufentanil.	Approved
Ruxolitinib	Ruxolitinib may increase the bradycardic activities of Sufentanil.	Approved
Sacubitril	The risk or severity of adverse effects can be increased when Sacubitril is combined with Sufentanil.	Approved
Safrazine	Sufentanil may increase the serotonergic activities of Safrazine.	Withdrawn
Saquinavir	The metabolism of Sufentanil can be decreased when combined with Saquinavir.	Approved, Investigational
Scopolamine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Scopolamine.	Approved
Scopolamine butylbromide	The risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Sufentanil.	Approved, Vet Approved
Secobarbital	The risk or severity of adverse effects can be increased when Secobarbital is combined with Sufentanil.	Approved, Vet Approved
Selegiline	Sufentanil may increase the serotonergic activities of Selegiline.	Approved, Investigational, Vet Approved
Sepranolone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Uc1010.	Investigational
Sertindole	The risk or severity of adverse effects can be increased when Sufentanil is combined with Sertindole.	Approved, Withdrawn
Sertraline	Sufentanil may increase the serotonergic activities of Sertraline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Sufentanil is combined with Sevoflurane.	Approved, Vet Approved
Sildenafil	The metabolism of Sufentanil can be decreased when combined with Sildenafil.	Approved, Investigational
Siltuximab	The serum concentration of Sufentanil can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Sufentanil can be increased when it is combined with Simeprevir.	Approved
Sodium Nitrite	The risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Sufentanil.	Approved
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved
Solifenacin	The risk or severity of adverse effects can be increased when Solifenacin is combined with Sufentanil.	Approved
Sotalol	Sotalol may increase the bradycardic activities of Sufentanil.	Approved
Spironolactone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Spironolactone.	Approved
St. John's Wort	The serum concentration of Sufentanil can be decreased when it is combined with St. John's Wort.	Nutraceutical
Stiripentol	The serum concentration of Sufentanil can be increased when it is combined with Stiripentol.	Approved
Streptokinase	The risk or severity of adverse effects can be increased when Streptokinase is combined with Sufentanil.	Approved
Succinylcholine	Succinylcholine may increase the bradycardic activities of Sufentanil.	Approved
Sulfisoxazole	The metabolism of Sufentanil can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sulpiride	The risk or severity of adverse effects can be increased when Sulpiride is combined with Sufentanil.	Approved
Suvorexant	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved
Tamsulosin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tamsulosin.	Approved, Investigational
Tandospirone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tandospirone.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tasimelteon.	Approved
Telaprevir	The metabolism of Sufentanil can be decreased when combined with Telaprevir.	Withdrawn
Telithromycin	The metabolism of Sufentanil can be decreased when combined with Telithromycin.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Telmisartan is combined with Sufentanil.	Approved, Investigational
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Sufentanil.	Approved
Terazosin	The risk or severity of adverse effects can be increased when Terazosin is combined with Sufentanil.	Approved
Tetrabenazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrabenazine.	Approved
Tetracaine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tetracaine.	Approved, Vet Approved
Tetrodotoxin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrodotoxin.	Investigational
Thalidomide	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Theobromine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Theobromine.	Approved
Thiamylal	The risk or severity of adverse effects can be increased when Sufentanil is combined with Thiamylal.	Approved, Vet Approved
Thiethylperazine	Thiethylperazine may increase the hypotensive activities of Sufentanil.	Withdrawn
Thiopental	The risk or severity of adverse effects can be increased when Thiopental is combined with Sufentanil.	Approved, Vet Approved
Thioridazine	The risk or severity of adverse effects can be increased when Thioridazine is combined with Sufentanil.	Withdrawn
Thiothixene	The risk or severity of adverse effects can be increased when Sufentanil is combined with Thiothixene.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tiagabine.	Approved
Tiapride	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tiapride.	Approved, Investigational
Ticlopidine	The metabolism of Sufentanil can be decreased when combined with Ticlopidine.	Approved
Ticrynafen	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ticrynafen.	Withdrawn
Timolol	Timolol may increase the bradycardic activities of Sufentanil.	Approved
Tiotropium	The risk or severity of adverse effects can be increased when Tiotropium is combined with Sufentanil.	Approved
Tizanidine	Tizanidine may increase the bradycardic activities of Sufentanil.	Approved
Tocilizumab	The serum concentration of Sufentanil can be decreased when it is combined with Tocilizumab.	Approved
Tofacitinib	Tofacitinib may increase the bradycardic activities of Sufentanil.	Approved, Investigational
Tolazoline	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tolazoline.	Approved, Vet Approved
Tolcapone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tolcapone.	Approved, Withdrawn
Toloxatone	Sufentanil may increase the serotonergic activities of Toloxatone.	Approved
Tolterodine	The risk or severity of adverse effects can be increased when Tolterodine is combined with Sufentanil.	Approved, Investigational
Tolvaptan	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tolvaptan.	Approved
Topiramate	The risk or severity of adverse effects can be increased when Sufentanil is combined with Topiramate.	Approved
Torasemide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Torasemide.	Approved
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Sufentanil.	Approved, Investigational
Trandolapril	The risk or severity of adverse effects can be increased when Trandolapril is combined with Sufentanil.	Approved
Trans-2-Phenylcyclopropylamine	Sufentanil may increase the serotonergic activities of Trans-2-Phenylcyclopropylamine.	Experimental
Tranylcypromine	Sufentanil may increase the serotonergic activities of Tranylcypromine.	Approved
Trazodone	The risk or severity of adverse effects can be increased when Trazodone is combined with Sufentanil.	Approved, Investigational
Tretinoin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Tretinoin.	Approved, Investigational, Nutraceutical
Triamterene	The risk or severity of adverse effects can be increased when Sufentanil is combined with Triamterene.	Approved
Triazolam	The risk or severity of adverse effects can be increased when Sufentanil is combined with Triazolam.	Approved
Trichlormethiazide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Trichlormethiazide.	Approved, Vet Approved
Trifluoperazine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Trifluoperazine.	Approved
Triflupromazine	The risk or severity of adverse effects can be increased when Triflupromazine is combined with Sufentanil.	Approved, Vet Approved
Trihexyphenidyl	The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Sufentanil.	Approved
Trimethaphan	The risk or severity of adverse effects can be increased when Trimethaphan is combined with Sufentanil.	Approved
Trimipramine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Trimipramine.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Triprolidine.	Approved
Tropicamide	The risk or severity of adverse effects can be increased when Tropicamide is combined with Sufentanil.	Approved
Trospium	The risk or severity of adverse effects can be increased when Trospium is combined with Sufentanil.	Approved
Tubocurarine	The risk or severity of adverse effects can be increased when Tubocurarine is combined with Sufentanil.	Approved
Ularitide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ularitide.	Investigational
Umeclidinium	The risk or severity of adverse effects can be increased when Umeclidinium is combined with Sufentanil.	Approved
Valproic Acid	The risk or severity of adverse effects can be increased when Valproic Acid is combined with Sufentanil.	Approved, Investigational
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Sufentanil.	Approved, Investigational
Vecuronium	The risk or severity of adverse effects can be increased when Vecuronium is combined with Sufentanil.	Approved
Venlafaxine	The metabolism of Sufentanil can be decreased when combined with Venlafaxine.	Approved
Verapamil	The metabolism of Sufentanil can be decreased when combined with Verapamil.	Approved
Vigabatrin	The risk or severity of adverse effects can be increased when Sufentanil is combined with Vigabatrin.	Approved
Voriconazole	The metabolism of Sufentanil can be decreased when combined with Voriconazole.	Approved, Investigational
Vortioxetine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Vortioxetine.	Approved
Zaleplon	The risk or severity of adverse effects can be increased when Sufentanil is combined with Zaleplon.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Ziconotide.	Approved
Zimelidine	Sufentanil may increase the serotonergic activities of Zimelidine.	Withdrawn
Ziprasidone	The metabolism of Sufentanil can be decreased when combined with Ziprasidone.	Approved
Zolpidem	Sufentanil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Sufentanil is combined with Zonisamide.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Sufentanil is combined with Zopiclone.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Sufentanil is combined with Zotepine.	Approved
Zuclopenthixol	The risk or severity of adverse effects can be increased when Sufentanil is combined with Zuclopenthixol.	Approved, Investigational

Food Interactions

Not Available

References

Synthesis Reference

Jacob Mathew, J. Killgore, "New methods for the synthesis of alfentanil, sufentanil, and remifentanil." U.S. Patent US20060149071, issued July 06, 2006.

US20060149071

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14846
KEGG Drug	D05938
KEGG Compound	C08022
PubChem Compound	41693
PubChem Substance	46504737
ChemSpider	38043
BindingDB	94503
ChEBI	9316
ChEMBL	CHEMBL658
Therapeutic Targets Database	DAP000357
PharmGKB	PA451527
IUPHAR	3534
Guide to Pharmacology	3534
Drug Product Database	12343
Drugs.com	http://www.drugs.com/cdi/sufentanil.html
Wikipedia	Sufentanil

ATC Codes

N01AH03 — Sufentanil

AHFS Codes

28:08.08

PDB Entries

Not Available

FDA label

Not Available

MSDS

Download (47.6 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Basic Science	Plasma Concentrations	1
1, 2	Terminated	Treatment	Opioids / Pain	1
2	Completed	Treatment	Anaesthesia therapy	1
2	Completed	Treatment	Major Upper or Lower Abdominal Surgery	1
2	Completed	Treatment	Pain	1
2	Completed	Treatment	Pregnant Women	1
2	Not Yet Recruiting	Treatment	Head Trauma	1
2	Recruiting	Treatment	Prenatal Diagnosis	1
2	Withdrawn	Treatment	Pain, Chronic	1
2, 3	Active Not Recruiting	Treatment	Cerebral Hypoperfusion / Intubation, Endotracheal / Premedication	1
2, 3	Active Not Recruiting	Treatment	Intubation, Endotracheal / Premedication	1
2, 3	Completed	Supportive Care	Healthy Volunteers / Pelvic Floor Disorders / Prolonged Labour	1
2, 3	Recruiting	Treatment	Myocardial Injury	1
3	Completed	Prevention	Normal Pregnancies	1
3	Completed	Treatment	Child Comfort / Intensive Care Units / Morphine / Pediatric	1
3	Completed	Treatment	Moderate-to-severe Acute Pain	1
3	Completed	Treatment	Pain, Acute	1
3	Completed	Treatment	Post Operative Pain	1
3	Completed	Treatment	Post-Operative Pain	3
3	Completed	Treatment	Postoperative pain	1
3	Not Yet Recruiting	Treatment	Obstetric Pain / Other Complications of Obstetric Anesthesia - Delivered	1
3	Recruiting	Treatment	Moderate-to-severe Acute Pain	1
3	Recruiting	Treatment	Lumbar epidural anesthesia therapy	1
4	Active Not Recruiting	Treatment	Driving Performance After Minor Ambulatory Surgery / Minor Surgical Procedures With Monitored Anesthesia Care	1
4	Completed	Not Available	Aortic Aneurysms	1
4	Completed	Basic Science	Anaesthesia therapy	1
4	Completed	Prevention	Aortic Valve Stenosis / Ischaemic Heart Diseases	1
4	Completed	Supportive Care	Pain	1
4	Completed	Supportive Care	Postoperative pain / Prophylaxis against postoperative nausea and vomiting	1
4	Completed	Treatment	Analgesics / Pain, Chronic / Postoperative pain	1
4	Completed	Treatment	Pain	3
4	Completed	Treatment	Postoperative pain	2
4	Completed	Treatment	Single Traumatic Limb Injury With Severe Pain (Score > 5/10 on Numerical Pain Scale)	1
4	Enrolling by Invitation	Supportive Care	Postoperative; Dysfunction Following Cardiac Surgery	1
4	Enrolling by Invitation	Treatment	Analgesia, Patient-Controlled / Arthroplasty / Gastric Resection	1
4	Not Yet Recruiting	Prevention	Postoperative Cognitive Dysfunction / Postoperative Delirium	1
4	Not Yet Recruiting	Treatment	Analgesia, Patient-Controlled / Anesthesia; Spinal / Intravenous Drug Delivery Systems / Lumbar epidural anesthesia / Morphine / Surgery, Colorectal	1
4	Recruiting	Prevention	Coronary Artery Bypass Graft Redo / General Anesthetic Drug Adverse Reaction	1
4	Recruiting	Supportive Care	Pregnancy	1
4	Recruiting	Treatment	Arteriovenous Malformations	1
4	Recruiting	Treatment	Labour Pain	1
4	Recruiting	Treatment	Numeric Pain Rating Scale > 5 / 10 / Severe Traumatic Pain	1
4	Recruiting	Treatment	Patients Ongoing Elective Abdominal Laparoscopy	1
4	Recruiting	Treatment	Postoperative pain	1
4	Terminated	Treatment	Analgesia / Sedation therapy	1
4	Terminated	Treatment	Thoracic Surgery	1
4	Unknown Status	Treatment	Adrenal Suppression / Hemodynamics Instability	1
Not Available	Completed	Not Available	Adequate Anesthesia With Unimpaired Motor Strength	1
Not Available	Completed	Not Available	Loss of Consciousness	1
Not Available	Completed	Diagnostic	Malignant Neoplasm of Prostate	1
Not Available	Completed	Prevention	Anaesthesia therapy / Pain	1
Not Available	Completed	Prevention	Kidney Donation/Transplantation	1
Not Available	Completed	Supportive Care	Epidural Block / Malignant Neoplasm of Esophagus / Oesophagectomy	1
Not Available	Completed	Supportive Care	Instrumental Delivery / Lumbar epidural anesthesia / Maternal Outcome / Neonatal Outcome	1
Not Available	Completed	Supportive Care	Total Knee Arthroplasty (TKA)	1
Not Available	Completed	Treatment	Anaesthesia therapy	1
Not Available	Completed	Treatment	Anesthesia Complications	1
Not Available	Completed	Treatment	Balanced Anesthesia	1
Not Available	Completed	Treatment	Ischaemic Heart Diseases	1
Not Available	Completed	Treatment	Labour Pain	1
Not Available	Completed	Treatment	Neoplasms, Pancreatic	1
Not Available	Completed	Treatment	Pediatric Ventricular Septal Defects	1
Not Available	Completed	Treatment	Post Operative Pain Management	1
Not Available	Not Yet Recruiting	Supportive Care	Cardiovascular Disease (CVD)	1
Not Available	Not Yet Recruiting	Treatment	C.Delivery; Surgery (Previous), Gynecological	1
Not Available	Not Yet Recruiting	Treatment	Liver Diseases / Neoplasms, Hepatic / Secondary Malignant Neoplasm of Liver	1
Not Available	Not Yet Recruiting	Treatment	Postoperative Complications	1
Not Available	Recruiting	Device Feasibility	Postoperative pain	1
Not Available	Recruiting	Prevention	Prophylaxis against postoperative nausea and vomiting	1
Not Available	Recruiting	Treatment	Labor Analgesia	1
Not Available	Recruiting	Treatment	Labour Pain	1
Not Available	Terminated	Diagnostic	Labour Pain	1
Not Available	Unknown Status	Health Services Research	Pregnancy	1
Not Available	Unknown Status	Supportive Care	Adjunct to general anesthesia therapy	1
Not Available	Unknown Status	Treatment	Haemodynamic Fluctuations During Off-pump CABG	1

Pharmacoeconomics

Manufacturers

Akorn inc
Baxter healthcare corp anesthesia and critical care
Hospira inc
Watson laboratories inc

Packagers

Dosage forms

Form	Route	Strength
Liquid	Epidural; Intravenous	50 mcg
Liquid	Intravenous	50 mcg
Injection	Epidural; Intravenous	.05 mg/mL
Injection	Epidural; Intravenous	50 ug/mL
Injection, solution	Epidural; Intravenous	50 ug/mL
Solution	Epidural; Intravenous	50 mcg
Tablet	Sublingual	15 μg

Prices

Unit description	Cost	Unit
Sufentanil citrate powder	18927.0USD	g
Sufenta 50 mcg/ml ampul	5.38USD	ml
Sufentanil 50 mcg/ml ampul	3.92USD	ml

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	97 °C	PhysProp
water solubility	76 mg/L (at 25 °C)	ROY,SD & FLYNN,GL (1988)
logP	3.95	SANGSTER (1993)
logS	-3.71	ADME Research, USCD

Predicted Properties

Property	Value	Source
Water Solubility	0.012 mg/mL	ALOGPS
logP	3.4	ALOGPS
logP	3.61	ChemAxon
logS	-4.5	ALOGPS
pKa (Strongest Basic)	8.86	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	32.78 Å²	ChemAxon
Rotatable Bond Count	8	ChemAxon
Refractivity	111.42 m³·mol^-1	ChemAxon
Polarizability	43.85 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9875
Blood Brain Barrier	+	0.9886
Caco-2 permeable	+	0.5201
P-glycoprotein substrate	Substrate	0.6673
P-glycoprotein inhibitor I	Inhibitor	0.8275
P-glycoprotein inhibitor II	Inhibitor	0.8387
Renal organic cation transporter	Non-inhibitor	0.5594
CYP450 2C9 substrate	Non-substrate	0.7923
CYP450 2D6 substrate	Non-substrate	0.9116
CYP450 3A4 substrate	Substrate	0.713
CYP450 1A2 substrate	Non-inhibitor	0.8954
CYP450 2C9 inhibitor	Non-inhibitor	0.7839
CYP450 2D6 inhibitor	Non-inhibitor	0.8416
CYP450 2C19 inhibitor	Non-inhibitor	0.5438
CYP450 3A4 inhibitor	Inhibitor	0.6293
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.6401
Ames test	Non AMES toxic	0.7695
Carcinogenicity	Non-carcinogens	0.8861
Biodegradation	Not ready biodegradable	0.9724
Rat acute toxicity	3.0968 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9793
hERG inhibition (predictor II)	Inhibitor	0.772

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-000i-0009000000-0f9e477eb2153eb20409	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-000i-0096000000-73641c83c08b872641cd	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-06ri-1981000000-b5f4aaab095cc6fc533c	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-03di-1900000000-2fdfd1d5fa6e43fa1604	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-03di-4900000000-bd92c052347dc0822a01	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as anilides. These are organic heterocyclic compounds derived from oxoacids RkE(=O)l(OH)m (l not 0) by replacing an OH group by the NHPh group or derivative formed by ring substitution.

Kingdom

Organic compounds

Super Class

Benzenoids

Class

Benzene and substituted derivatives

Sub Class

Anilides

Direct Parent

Anilides

Alternative Parents

Aralkylamines / Piperidines / Thiophenes / Tertiary carboxylic acid amides / Heteroaromatic compounds / Trialkylamines / Amino acids and derivatives / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds

Substituents

Anilide / Aralkylamine / Piperidine / Tertiary carboxylic acid amide / Heteroaromatic compound / Thiophene / Amino acid or derivatives / Carboxamide group / Tertiary amine / Tertiary aliphatic amine

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

piperidines, thiophenes, ether, anilide (CHEBI:9316 )

Targets

Details

1. Mu-type opioid receptor

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: agonist

General Function:: Voltage-gated calcium channel activity
Specific Function:: Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:: OPRM1
Uniprot ID:: P35372
Uniprot Name:: Mu-type opioid receptor
Molecular Weight:: 44778.855 Da

References

Hurle MA: Changes in the expression of G protein-coupled receptor kinases and beta-arrestin 2 in rat brain during opioid tolerance and supersensitivity. J Neurochem. 2001 Apr;77(2):486-92. [PubMed:11299311 ]
Levron JC: [Pharmacokinetics and pharmacodynamics of morphinomimetics in the central nervous system]. Agressologie. 1991;32(6-7):318-20. [PubMed:1688220 ]
Ilien B, Galzi JL, Mejean A, Goeldner M, Hirth C: A mu-opioid receptor-filter assay. Rapid estimation of binding affinity of ligands and reversibility of long-lasting ligand-receptor complexes. Biochem Pharmacol. 1988 Oct 15;37(20):3843-51. [PubMed:2847746 ]
Colpaert FC, Leysen JE, Michiels M, van den Hoogen RH: Epidural and intravenous sufentanil in the rat: analgesia, opiate receptor binding, and drug concentrations in plasma and brain. Anesthesiology. 1986 Jul;65(1):41-9. [PubMed:3014923 ]
Leysen JE, Gommeren W: In vitro binding properties of 3H-sufentanil, a superior ligand for the mu-opiate receptor. Arch Int Pharmacodyn Ther. 1982 Dec;260(2):287-9. [PubMed:6131653 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Details

2. Delta-type opioid receptor

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: agonist

General Function:: Opioid receptor activity
Specific Function:: G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:: OPRD1
Uniprot ID:: P41143
Uniprot Name:: Delta-type opioid receptor
Molecular Weight:: 40368.235 Da

References

Freye E, Latasch L, Portoghese PS: The delta receptor is involved in sufentanil-induced respiratory depression--opioid subreceptors mediate different effects. Eur J Anaesthesiol. 1992 Nov;9(6):457-62. [PubMed:1330549 ]
Zhu J, Xue JC, Law PY, Claude PA, Luo LY, Yin J, Chen C, Liu-Chen LY: The region in the mu opioid receptor conferring selectivity for sufentanil over the delta receptor is different from that over the kappa receptor. FEBS Lett. 1996 Apr 15;384(2):198-202. [PubMed:8612823 ]

Details

3. Kappa-type opioid receptor

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: other

General Function:: Opioid receptor activity
Specific Function:: G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:: OPRK1
Uniprot ID:: P41145
Uniprot Name:: Kappa-type opioid receptor
Molecular Weight:: 42644.665 Da

References

Zhu J, Xue JC, Law PY, Claude PA, Luo LY, Yin J, Chen C, Liu-Chen LY: The region in the mu opioid receptor conferring selectivity for sufentanil over the delta receptor is different from that over the kappa receptor. FEBS Lett. 1996 Apr 15;384(2):198-202. [PubMed:8612823 ]
Chang HM, Berde CB, Holz GG 4th, Steward GF, Kream RM: Sufentanil, morphine, met-enkephalin, and kappa-agonist (U-50,488H) inhibit substance P release from primary sensory neurons: a model for presynaptic spinal opioid actions. Anesthesiology. 1989 Apr;70(4):672-7. [PubMed:2467589 ]

Enzymes

Details

1. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Vitamin d3 25-hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:: CYP3A4
Uniprot ID:: P08684
Uniprot Name:: Cytochrome P450 3A4
Molecular Weight:: 57342.67 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 16:52

Get DrugBank to go!

Structure for DB00708 (Sufentanil)

Targets

References

References

References

Enzymes

References